#United States #Salt Lake City #Sera Prognostics #Maternal Health #PreTRM Test

Sera Prognostics Reports First Quarter 2025 Financial Results

Sera Prognostics Inc., known as The Pregnancy Company®, has reported its financial results for the first quarter of 2025, showcasing a significant advance in its mission to improve maternal and neonatal health through innovative biomarker insights. This announcement comes as Sera expands its engagement with health payers and administrators to enhance the usage of its proprietary PreTRM® Test.

Recent Developments

In light of recent successes, including positive results from the comprehensive Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study, Sera is elevating its outreach to managed care plans. Notably, the company is aiming to tap into the Medicaid segment, which represents about 50% of the market potential for the PreTRM Test. Currently, Sera is in talks with Medicaid plans across three states to launch pilot implementations of this critical test.

Sera Prognostics also anticipates a strong presence at the upcoming American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical Meeting, scheduled for May 16-18, where it aims to foster interest in the continued generation of evidence supporting the PreTRM test-and-treat model. Additionally, Jeff Elliott has been appointed to the Board of Directors, enhancing the depth of expertise within the company focused on scaling its operations.

Financial Performance Summary

During the first quarter of 2025, Sera reported revenue of $38,000, a marked increase from zero in the same period of 2024, indicating a successful start in monetizing its innovative healthcare solutions. However, the total operating expenses stood at $9.3 million, slightly higher than the previous year’s $9.1 million. Notably, research and development costs decreased to $3.3 million compared to $3.7 million in the prior year, reflecting a strategic reduction as the company focuses on finalizing clinical study analyses from the PRIME study.

Selling, general, and administrative expenses increased slightly to $5.9 million from $5.4 million, aligning with Sera's efforts to harness growth by strategically adding talent and preparing for the upcoming publication of the PRIME study findings. The net loss for this quarter was $8.2 million, a minor increase compared to the loss of $8.1 million the previous year. As of March 31, 2025, Sera holds $114.2 million in cash, cash equivalents, and marketable securities, putting the company in a strong financial position to pursue its objectives.

Looking Ahead

Sera Prognostics’ leadership, particularly Zhenya Lindgardt, expressed optimism regarding the future, emphasizing the potential for Medicaid providers to recognize the PreTRM Test's impact on healthcare cost savings and patient outcomes. This initiative represents a paradigm shift in the management of premature births, where early, informed interventions can drastically improve both maternal and neonatal health outcomes.

The PreTRM Test, known for its accuracy and early prediction capabilities concerning spontaneous preterm deliveries, stands as a cornerstone of Sera’s innovation strategy, promoting personalized healthcare for expectant mothers. As Sera continues to gather momentum, its commitment to precision pregnancy care exemplifies a groundbreaking approach to tackling the public health challenge of preterm births, which affects over 10% of births in the U.S.

In conclusion, as Sera Prognostics embarks on this promising journey, its ability to leverage strategic partnerships, expand its market presence, and maintain cutting-edge research will play pivotal roles in its mission to enhance maternal and neonatal health across the nation. Strong upcoming appearances and discussions at major medical conferences are expected to propel the company further into the healthcare landscape, fostering broader acceptance and utilization of its vital services.